MedAbome is a preclinical-stage biopharmaceutical company dedicated to developing innovative therapeutic antibody candidates and antibody-related therapies to meet urgent unmet medical needs. 

Located in the San Francisco Bay Area, MedAbome specializes in the discovery and development of monoclonal antibodies (mAbs) that target rare, disease-specific epitopes. Leveraging advanced hybridoma technology along with our proprietary Live Cell Immunization and Live Cell High-Throughput Screening (LCI-HTS) platforms, we are building robust pipelines of First-in-Class (FIC) biopharmaceutical candidates. 

Our research spans both oncology and non-oncology indications, including inflammatory and autoimmune diseases — driven by our commitment to deliver impactful therapies to patients in need. 

Copyright © 2025 MedAbome, Inc. - All Rights Reserved.